- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04588441
The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19
June 16, 2023 updated by: University of Florida
Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19 (The ARCTIC Trial)
This is a phase II study to test adenosine efficacy for down-regulation of the overwhelming inflammation of COVID-19 in the lungs as reflected by clinical recovery of lung function; resolution of clinically relevant markers of lung function, and resolution of systemic markers of inflammation and coagulation.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Amy Gunnett
- Phone Number: (352) 273-8911
- Email: agunnett@anest.ufl.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 105 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adult (≥ 18 years old) male and female patients with diagnosed COVID-19 respiratory infection, verified by culture/swab RNA. Impending ARDS respiratory collapse with progressive increasing oxygen requirements, and in line with sub-study as defined below.
- Patients intubated within the prior 24 hours.
- Hemodynamically stable (not requiring vasopressors or catecholamine agents to support systemic blood pressure; no existing shock defined as BP < 100 mmHg systolic).
- In-place continuous arterial line for blood sampling.
Exclusion Criteria:
- Younger than 18 years old.
- Prisoners
- Pregnant women.
- Unable to obtain next of kin consent.
- End-stage cardiac disease with COVID-19.
- Non COVID-related causes of ARDS/respiratory failure, septic shock, or post trauma shock, respiratory failure after blood transfusion or surgery.
- Unstable asthma or history of frequent/poorly controlled asthmatic attacks.
- Not expected to live more than 6 months due to underlying condition such as cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adenosine
Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer
|
Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days).
Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improved COVID-19 symptoms
Time Frame: Day 50
|
Improved COVID-19 symptoms measured by alive v. mortality, not hospitalized, or free of respiratory failure.
|
Day 50
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bruce Spiess, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2023
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
October 13, 2020
First Submitted That Met QC Criteria
October 13, 2020
First Posted (Actual)
October 19, 2020
Study Record Updates
Last Update Posted (Estimated)
June 19, 2023
Last Update Submitted That Met QC Criteria
June 16, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Purinergic Agents
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Adenosine
Other Study ID Numbers
- IRB202002127
- OCR39505 (Other Identifier: UF OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress
-
University Hospital, Clermont-FerrandWithdrawn
-
Hennepin Healthcare Research InstituteCompletedAcute Respiratory DistressUnited States
-
University Hospital, BordeauxCompleted
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, BrestCompletedHypoxemic Acute Respiratory Distress | Infant Between 1 Month and 24 Months Old | Child Between 2 and 15 Years OldFrance
-
Intermountain Health Care, Inc.UnknownRespiratory Failure | Acute Respiratory Distress Syndrome (ARDS) | Acute Lung Injury (ALI)United States
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Western University, CanadaEnrolling by invitationCOVID-19 Acute Respiratory Distress SyndromeCanada
-
Ain Shams UniversityCompletedCOVID-19 Acute Respiratory Distress SyndromeEgypt
Clinical Trials on Adenosine
-
St. Louis UniversityAstellas Pharma US, Inc.; University of FloridaCompletedCoronary Artery DiseaseUnited States
-
Hillel Yaffe Medical CenterUnknown
-
BiogenTerminatedHeart Failure | Renal InsufficiencyUnited States
-
National Research Council, SpainHospital General Universitario Reina Sofía de MurciaCompleted
-
Cedars-Sinai Medical CenterAstellas Pharma US, Inc.CompletedCoronary Artery DiseaseUnited States
-
Midwest Heart FoundationGE Healthcare; Astellas Pharma US, Inc.Terminated
-
Queen Margaret UniversityPomeGreatUnknownObesity | Cardiovascular Disease | DiabetesUnited Kingdom
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
BayerCompletedHypertension, PulmonaryItaly, Spain, France, Germany, Portugal, United Kingdom
-
Jennifer Cowger , MD, MSPOM Wonderful LLCTerminatedHeart Failure | CardiomyopathyUnited States